FDA Adds Rare Vision-Loss Warning to Ozempic, Wegovy and Other GLP-1 Drugs
The FDA is requiring a warning about a rare optic nerve condition called NAION on GLP-1 drugs including Ozempic and Wegovy. Regulators say the cause is unclear, and drugmakers dispute a causal link.
